$20.85 -0.9 -4.0%
Last Trade - 01/03/21
| Market Cap | ÂŁ388.5m |
| Enterprise Value | ÂŁ304.9m |
| Revenue | ÂŁn/a |
| Position in Universe | 3412th / 6633 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway, an alternative glucose metabolism pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. Its other product candidates include AT-007, AT-003 and AT-104. AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | January 20, 2016 |
| Public Since | May 9, 2019 |
| No. of Shareholders: | 125 |
| No. of Employees: | 11 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Market |
| Shares in Issue | 25,943,661 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 545 5TH AVENUE SUITE 1400, NEW YORK, 10017, United States |
| Web | http://www.appliedtherapeutics.com/ |
| Phone | +1 212 2209319 |
| Contact | Maeve Conneighton (IR Contact Officer) |
| Auditors | Ernst & Young LLP |
As of 01/03/21, shares in Applied Therapeutics Inc are trading at $20.85, giving the company a market capitalisation of ÂŁ388.5m. This share price information is delayed by 15 minutes.
Shares in Applied Therapeutics Inc are currently trading at $20.85 and the price has moved by -49.82% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Applied Therapeutics Inc price has moved by -59.31% over the past year.
There are no analysts currently covering Applied Therapeutics Inc.
Applied Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:
Applied Therapeutics Inc does not currently pay a dividend.
Applied Therapeutics Inc does not currently pay a dividend.
Applied Therapeutics Inc does not currently pay a dividend.
To buy shares in Applied Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Applied Therapeutics Inc are currently trading at $20.85, giving the company a market capitalisation of ÂŁ388.5m.
Here are the trading details for Applied Therapeutics Inc:
Based on an overall assessment of its quality, value and momentum, Applied Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Applied Therapeutics Inc are currently priced at $20.85. At that level they are trading at 0.139% discount to the analyst consensus target price of 0.00.
Analysts covering Applied Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -4.534 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Applied Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -22.34%. At the current price of $20.85, shares in Applied Therapeutics Inc are trading at -21.94% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Applied Therapeutics Inc.
Applied Therapeutics Inc's management team is headed by:
Here are the top five shareholders of Applied Therapeutics Inc based on the size of their shareholding:
